Kyle Concannon, MD

Samantha tried Ivermectin after feeling social media pressure. Her reality? It didn't work and her cancer progressed. A vital, honest perspective. Support ➡️ Giving.CU.EDU/CrackingCancer youtu.be/zJhK6J1cZ3k

Ivermectin works by jamming a cellular "door" open that paralyzes parasites. The kicker? Humans don’t even have those doors in our cells. Science! 🧬 Support ➡️ Giving.CU.EDU/CrackingCancer youtu.be/zJhK6J1cZ3k

It’s really hard to know what to trust regarding ivermectin. Listen below!

So excited to share this episode and discuss ivermectin through an objective lens rooted in mutual understanding. Patients face tremendous judgment, yet they’re the ones who live with the consequences of taking, or not taking, medications they think may help.

Dr. Misty Shields breaks down why Platinum + Etoposide has been the standard since 1985: it damages DNA faster than the cancer can repair it. Catastrophic for the cancer, vital for the patient. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/0fbg28XR0S0

SCLC research just leaped 40 years forward. Adding immunotherapy previously added 2-3 months. Now, "BiTEs" like Tarlatamab are doubling overall survival in clinical studies. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/0fbg28XR0S0

@LauraJBook @DFEGFRcenter @EGFRResisters @LUNGevity My email is Kyle.concannon@cuanschutz.edu. Let’s set up a time to chat!

@kyleconcannonMD @DFEGFRcenter @EGFRResisters @LUNGevity How can we support you?

I've seen similar studies publicized or studied by @DFEGFRcenter, @egfrresisters & investigator Dr. Lovly to study persister cells, @egfrresisters & @LUNGevity for Dr. Brea to study CarTs. When will we start to see these new techniques in trials?

@YoungLungCancer @maraantonoff @EGFRResisters @ALKPositiveinc @IASLC It also may not…

@maraantonoff @EGFRResisters @ALKPositiveinc @IASLC What do we do when misleading headlines are coming from those involved in the study? Misleading clickbait headlines is exactly how something like this gets picked up and goes viral.

Crucial reality check from @lungoncdoc: Association ≠ causation‼️ Headlines linking healthy diet/pesticides to young onset lung cancer wildly overstate limited observations without proper controls, confounder adjustment, or any assessment of causality. instagram.com/reel/DYATLHSvr…

Half of patients with Stage IV lung cancer don't receive any life-extending treatments. For @nytimes , I explored this sobering statistic and why so many people with the nation's deadliest cancer go without care. According to a new @JAMAOnc study of 250,000+ Medicare patients, ❌ 1/3 of patients never see an oncologist. ❌ Rural, unmarried, and minority populations were the least likely to be treated. ❌ 40% die within 3 months of diagnosis, suggesting that many patients are diagnosed far too late. (Think low rates of lung cancer screening and longstanding delays between a suspicious scan and a diagnosis.) Why does this matter? We are in a "golden age" of lung cancer treatment. Immunotherapy and targeted therapies are incredibly effective and well-tolerated. In fact, with a daily pill, some patients can live for years after being diagnosed. Lung cancer is no longer a death sentence, but access issues, fatalism, and stigma are keeping these promising medications out of reach. In medicine, there's always been this gap between scientific breakthroughs and the patient bedside. And I believe that improving access and uptake of health care is one of the most challenging and important issues of our time. @kyleconcannonMD @DrewMoghanaki @muschollings Read the full story here: nytimes.com/2026/05/07/wel…

#BrainCancerAwarenessMonth: Peter Fecci, MD, PhD, CU Anschutz Cancer Center member and chair of the Department of Neurosurgery (@CUNSGY), shares the origins of cancer in the brain and how different types are treated: bit.ly/4tTxhyF

Missed out on ⁦⁦@AACR⁩? ⁦@maxdoppelt⁩ and @kyleconcannonmd discuss attending the annual conference! Major scientific advancements are showcased there every year. A must listen if you plan on attending as a patient/advocate! podcasts.apple.com/us/podcast/the…

@CTSPeng @CellCellPress Wow congratulations! It will be great to see how different molecular and therapeutic contexts influence HER-family dimers and subsequent targeting strategies. Very cool!

Excited to share our work on ErbB receptors published today @CellCellPress! Using multicolor, photostable UCNPs, we perform long-term (>15 min) single-particle tracking of EGFR, HER2, and HER3, enabling direct visualization of dimerization in live cells. cell.com/cell/fulltext/…

The "I don't want to be a burden" mindset is the biggest trap in oncology. Matt shares how he tried to go it alone to protect his fiancé, only to realize that isolation helps no one. Bring someone to the room. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/0fbg28XR0S0

Huge thanks for @drshieldsmd and Matt Baker for coming on @Cracking_Cancer to discuss treating and having small cell lung cancer. We’ve come so far but chemo is still a major backbone of our treatments.

Many patients undergo radiation treatment during their cancer journey, but what it is? What’s it like actually getting radiation and whats the difference between the different types of radiation? Bill Thach and Dr. Tim Waxweiler dig into the details! podcasts.apple.com/us/podcast/the…

Don't let assumptions fuel your anxiety. Come in curious. Oncologists have more time than most specialists—they want to be your educator. Start with 2 questions and let the conversation flow. Support ➡️ Giving.CU.EDU/CrackingCancer youtu.be/Hg4UTm8CI5U

Research often focuses on "Quantity of Life," but for AYAs, the definition of "Quality" is personal and shifting. We need to fund research into AYA Biology, one size does NOT fit all. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/k5rKr-S-TpE

Isolation isn't just "loneliness"—it's a clinical risk. JJ shares how being on "incurable treatment" at 27 led to dark thoughts and stunted growth. Finding the AYA community was the pivot. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/k5rKr-S-TpE

Oncology brochures often feature retirees, but what if you're 27? JJ shares the struggle of navigating "elderly-focused" resources while dealing with permanent neuropathy. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/k5rKr-S-TpE